Significant Ownership of Two Seas Capital LP
- Signature and title
- /s/ Sina Toussi - Sina Toussi/Managing Member of Two Seas Capital GP LLC, its general partner
- Location
- Rye, NY
- Schedule 13D/G summary
- Recent SEC Schedule 13D/G filings for Two Seas Capital LP, focused on large-stake beneficial ownership disclosures and amendments.
Manager identity
Large-stake snapshot
Follow Filing Activity
Follow Two Seas Capital LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Two Seas Capital LP
Significant Ownership of Two Seas Capital LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OMEX | ODYSSEY MARINE EXPLORATION INC | Common Stock, par value $0.0001 per share | 10% | $4,814,822 | +$635,048 | 5,857,448 | +15% | Two Seas Capital LP | 08 Apr 2026 |
| PAVM | PAVmed Inc. | Common Stock, $0.001 par value per share | 10% | $157,733 | 657,219 | Two Seas Capital LP | 31 Mar 2026 | ||
| GCI | Gannett Co., Inc. | Common Stock, par value $0.01 per share | 9.6% | $58,565,965 | +$12,183,500 | 14,180,621 | +26% | Two Seas Capital LP | 30 Sep 2025 |
| ABUS | Arbutus Biopharma Corporation | Common Shares, without par value | 9.4% | $79,797,435 | +$25,664,056 | 18,557,543 | +47% | Two Seas Capital LP | 31 Mar 2026 |
| CLMT | Calumet, Inc. | Common Stock, par value $0.01 per share | 9.3% | $161,073,775 | +$26,765,794 | 8,098,229 | +20% | Two Seas Capital LP | 31 Dec 2025 |
| MDRX | Veradigm Inc. | Common Stock, par value $0.01 per share | 6.9% | $36,229,165 | +$7,986,025 | 7,469,931 | +28% | Two Seas Capital LP | 31 Dec 2025 |
| NKTR | NEKTAR THERAPEUTICS | Common Stock, $0.0001 par value | 6.8% | $144,979,172 | 1,959,178 | Two Seas Capital LP | 31 Mar 2026 | ||
| INDV | INDIVIOR PLC | Ordinary Shares, $0.50 nominal value per share | 5% | $203,438,218 | -$27,837,500 | 6,211,854 | -12% | Two Seas Capital LP | 23 Dec 2025 |
| ESPR | Esperion Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.7% | $25,836,769 | -$543,915 | 9,749,724 | -2.1% | Two Seas Capital LP | 30 Sep 2025 |
| CORZ | Core Scientific, Inc. | Common Stock, par value $0.00001 per share | 4.4% | $209,212,279 | -$58,852,640 | 13,984,778 | -22% | Two Seas Capital LP | 23 Apr 2026 |
| ADAP | Adaptimmune Therapeutics PLC | Ordinary Shares, par value GBP 0.001 per share | 0% | $0 | -$17,612,947 | 0 | -100% | Two Seas Capital LP | 30 Sep 2025 |
| AVDL | AVADEL PHARMACEUTICALS PLC | Ordinary Shares, nominal value $0.01 per share | 0% | $0 | -$132,210,990 | 0 | -100% | Two Seas Capital LP | 31 Dec 2025 |
Schedules 13D/G Reported by Two Seas Capital LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.